Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Hold” by Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus rating of “Hold” by the four ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $16.67.

ATRA has been the topic of several analyst reports. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and dropped their price target for the company from $25.00 to $18.00 in a research note on Friday, August 16th. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Finally, Canaccord Genuity Group raised their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

Atara Biotherapeutics Stock Up 8.1 %

ATRA opened at $11.47 on Monday. The firm has a market cap of $66.07 million, a price-to-earnings ratio of -0.44 and a beta of 0.50. Atara Biotherapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The company’s 50-day moving average price is $9.19 and its 200 day moving average price is $10.11.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter last year, the company earned ($16.50) EPS. Research analysts anticipate that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics in the second quarter valued at approximately $53,000. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the second quarter valued at approximately $79,000. State Street Corp boosted its holdings in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. FMR LLC boosted its holdings in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares in the last quarter. Finally, Delap Wealth Advisory LLC bought a new position in shares of Atara Biotherapeutics in the first quarter valued at approximately $29,000. 70.90% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.